Michael Pellini is currently a managing partner at Section 32, a venture capital fund, and chairman of Foundation Medicine. Michael joined Foundation Medicine as president and chief executive officer in May 2011 and transitioned to chairman in February 2017. As a physician with more than 20 years of operating experience with companies at the forefront of the clinical diagnostics and laboratory industries, Michael brings a breadth of understanding in personalized medicine, with a particular interest and focus in oncology. He currently serves as a member of the board of directors for Mass BIO and the Personalized Medicine Coalition, in addition to his board chair position with Foundation Medicine. Michael is a member of the President’s Leadership Council for the Sydney Kimmel Medical School at Thomas Jefferson University.